Cargando…

Lost in translation: returning germline genetic results in genome-scale cancer research

BACKGROUND: The return of research results (RoR) remains a complex and well-debated issue. Despite the debate, actual data related to the experience of giving individual results back, and the impact these results may have on clinical care and health outcomes, is sorely lacking. Through the work of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Johns, Amber L., McKay, Skye H., Humphris, Jeremy L., Pinese, Mark, Chantrill, Lorraine A., Mead, R. Scott, Tucker, Katherine, Andrews, Lesley, Goodwin, Annabel, Leonard, Conrad, High, Hilda A., Nones, Katia, Patch, Ann-Marie, Merrett, Neil D., Pavlakis, Nick, Kassahn, Karin S., Samra, Jaswinder S., Miller, David K., Chang, David K., Pajic, Marina, Pearson, John V., Grimmond, Sean M., Waddell, Nicola, Zeps, Nikolajs, Gill, Anthony J., Biankin, Andrew V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408494/
https://www.ncbi.nlm.nih.gov/pubmed/28454591
http://dx.doi.org/10.1186/s13073-017-0430-4
_version_ 1783232319253905408
author Johns, Amber L.
McKay, Skye H.
Humphris, Jeremy L.
Pinese, Mark
Chantrill, Lorraine A.
Mead, R. Scott
Tucker, Katherine
Andrews, Lesley
Goodwin, Annabel
Leonard, Conrad
High, Hilda A.
Nones, Katia
Patch, Ann-Marie
Merrett, Neil D.
Pavlakis, Nick
Kassahn, Karin S.
Samra, Jaswinder S.
Miller, David K.
Chang, David K.
Pajic, Marina
Pearson, John V.
Grimmond, Sean M.
Waddell, Nicola
Zeps, Nikolajs
Gill, Anthony J.
Biankin, Andrew V.
author_facet Johns, Amber L.
McKay, Skye H.
Humphris, Jeremy L.
Pinese, Mark
Chantrill, Lorraine A.
Mead, R. Scott
Tucker, Katherine
Andrews, Lesley
Goodwin, Annabel
Leonard, Conrad
High, Hilda A.
Nones, Katia
Patch, Ann-Marie
Merrett, Neil D.
Pavlakis, Nick
Kassahn, Karin S.
Samra, Jaswinder S.
Miller, David K.
Chang, David K.
Pajic, Marina
Pearson, John V.
Grimmond, Sean M.
Waddell, Nicola
Zeps, Nikolajs
Gill, Anthony J.
Biankin, Andrew V.
author_sort Johns, Amber L.
collection PubMed
description BACKGROUND: The return of research results (RoR) remains a complex and well-debated issue. Despite the debate, actual data related to the experience of giving individual results back, and the impact these results may have on clinical care and health outcomes, is sorely lacking. Through the work of the Australian Pancreatic Cancer Genome Initiative (APGI) we: (1) delineate the pathway back to the patient where actionable research data were identified; and (2) report the clinical utilisation of individual results returned. Using this experience, we discuss barriers and opportunities associated with a comprehensive process of RoR in large-scale genomic research that may be useful for others developing their own policies. METHODS: We performed whole-genome (n = 184) and exome (n = 208) sequencing of matched tumour-normal DNA pairs from 392 patients with sporadic pancreatic cancer (PC) as part of the APGI. We identified pathogenic germline mutations in candidate genes (n = 130) with established predisposition to PC or medium–high penetrance genes with well-defined cancer associated syndromes or phenotypes. Variants from candidate genes were annotated and classified according to international guidelines. Variants were considered actionable if clinical utility was established, with regard to prevention, diagnosis, prognostication and/or therapy. RESULTS: A total of 48,904 germline variants were identified, with 2356 unique variants undergoing annotation and in silico classification. Twenty cases were deemed actionable and were returned via previously described RoR framework, representing an actionable finding rate of 5.1%. Overall, 1.78% of our cohort experienced clinical benefit from RoR. CONCLUSION: Returning research results within the context of large-scale genomics research is a labour-intensive, highly variable, complex operation. Results that warrant action are not infrequent, but the prevalence of those who experience a clinical difference as a result of returning individual results is currently low. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-017-0430-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5408494
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54084942017-05-02 Lost in translation: returning germline genetic results in genome-scale cancer research Johns, Amber L. McKay, Skye H. Humphris, Jeremy L. Pinese, Mark Chantrill, Lorraine A. Mead, R. Scott Tucker, Katherine Andrews, Lesley Goodwin, Annabel Leonard, Conrad High, Hilda A. Nones, Katia Patch, Ann-Marie Merrett, Neil D. Pavlakis, Nick Kassahn, Karin S. Samra, Jaswinder S. Miller, David K. Chang, David K. Pajic, Marina Pearson, John V. Grimmond, Sean M. Waddell, Nicola Zeps, Nikolajs Gill, Anthony J. Biankin, Andrew V. Genome Med Research BACKGROUND: The return of research results (RoR) remains a complex and well-debated issue. Despite the debate, actual data related to the experience of giving individual results back, and the impact these results may have on clinical care and health outcomes, is sorely lacking. Through the work of the Australian Pancreatic Cancer Genome Initiative (APGI) we: (1) delineate the pathway back to the patient where actionable research data were identified; and (2) report the clinical utilisation of individual results returned. Using this experience, we discuss barriers and opportunities associated with a comprehensive process of RoR in large-scale genomic research that may be useful for others developing their own policies. METHODS: We performed whole-genome (n = 184) and exome (n = 208) sequencing of matched tumour-normal DNA pairs from 392 patients with sporadic pancreatic cancer (PC) as part of the APGI. We identified pathogenic germline mutations in candidate genes (n = 130) with established predisposition to PC or medium–high penetrance genes with well-defined cancer associated syndromes or phenotypes. Variants from candidate genes were annotated and classified according to international guidelines. Variants were considered actionable if clinical utility was established, with regard to prevention, diagnosis, prognostication and/or therapy. RESULTS: A total of 48,904 germline variants were identified, with 2356 unique variants undergoing annotation and in silico classification. Twenty cases were deemed actionable and were returned via previously described RoR framework, representing an actionable finding rate of 5.1%. Overall, 1.78% of our cohort experienced clinical benefit from RoR. CONCLUSION: Returning research results within the context of large-scale genomics research is a labour-intensive, highly variable, complex operation. Results that warrant action are not infrequent, but the prevalence of those who experience a clinical difference as a result of returning individual results is currently low. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-017-0430-4) contains supplementary material, which is available to authorized users. BioMed Central 2017-04-28 /pmc/articles/PMC5408494/ /pubmed/28454591 http://dx.doi.org/10.1186/s13073-017-0430-4 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Johns, Amber L.
McKay, Skye H.
Humphris, Jeremy L.
Pinese, Mark
Chantrill, Lorraine A.
Mead, R. Scott
Tucker, Katherine
Andrews, Lesley
Goodwin, Annabel
Leonard, Conrad
High, Hilda A.
Nones, Katia
Patch, Ann-Marie
Merrett, Neil D.
Pavlakis, Nick
Kassahn, Karin S.
Samra, Jaswinder S.
Miller, David K.
Chang, David K.
Pajic, Marina
Pearson, John V.
Grimmond, Sean M.
Waddell, Nicola
Zeps, Nikolajs
Gill, Anthony J.
Biankin, Andrew V.
Lost in translation: returning germline genetic results in genome-scale cancer research
title Lost in translation: returning germline genetic results in genome-scale cancer research
title_full Lost in translation: returning germline genetic results in genome-scale cancer research
title_fullStr Lost in translation: returning germline genetic results in genome-scale cancer research
title_full_unstemmed Lost in translation: returning germline genetic results in genome-scale cancer research
title_short Lost in translation: returning germline genetic results in genome-scale cancer research
title_sort lost in translation: returning germline genetic results in genome-scale cancer research
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5408494/
https://www.ncbi.nlm.nih.gov/pubmed/28454591
http://dx.doi.org/10.1186/s13073-017-0430-4
work_keys_str_mv AT johnsamberl lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT mckayskyeh lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT humphrisjeremyl lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT pinesemark lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT chantrilllorrainea lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT meadrscott lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT tuckerkatherine lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT andrewslesley lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT goodwinannabel lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT leonardconrad lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT highhildaa lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT noneskatia lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT patchannmarie lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT merrettneild lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT pavlakisnick lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT kassahnkarins lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT samrajaswinders lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT millerdavidk lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT changdavidk lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT pajicmarina lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT pearsonjohnv lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT grimmondseanm lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT waddellnicola lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT zepsnikolajs lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT gillanthonyj lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch
AT biankinandrewv lostintranslationreturninggermlinegeneticresultsingenomescalecancerresearch